|1.||Ghose, Romi: 5 articles (01/2014 - 01/2009)|
|2.||Guo, Tao: 4 articles (01/2014 - 01/2009)|
|3.||Gandhi, Adarsh: 3 articles (11/2012 - 05/2011)|
|4.||Ozawa, Shogo: 2 articles (01/2015 - 02/2003)|
|5.||Morgan, Edward T: 2 articles (04/2014 - 01/2014)|
|6.||Merrell, Matthew D: 2 articles (04/2014 - 01/2014)|
|7.||Nyagode, Beatrice A: 2 articles (04/2014 - 01/2014)|
|8.||Cherrington, Nathan J: 2 articles (04/2014 - 01/2008)|
|9.||Zgheib, Nathalie K: 2 articles (01/2014 - 07/2013)|
|10.||Shah, Pranav: 2 articles (01/2014 - 07/2011)|
|2.||Drug Toxicity (Drug Safety)
02/01/2008 - "This review tries to define potential fields in the therapy of major medical conditions where genotyping (or phenotyping) of genetically polymorphic DMEs might be beneficial for drug safety or therapeutic outcome. "
01/01/2014 - "Moreover, the genetic variability of DMEs causes important interindividual differences in drug and metabolite exposure, drug response, and risk of adverse drug reactions. "
01/01/2014 - "Herein, we provide an update on the genetic polymorphisms of DMEs that were studied in Lebanon and their impact on drug toxicity and efficacy. "
01/01/2014 - "Differential expression of various drug-metabolizing enzymes (DMEs) in the human liver may cause deviations of pharmacokinetic profiles, resulting in interindividual variability of drug toxicity and/or efficacy. "
|3.||Liver Diseases (Liver Disease)
01/01/2014 - "Altered regulation of DMEs in liver diseases contributes to the development of powerful in vitro and in vivo tools to predict drug responses and options for improved drug delivery and development. "
01/01/2014 - "Conclusively, this review aims to improve understanding on the regulation of DMEs in liver diseases and on corresponding implications in drug disposition, including novel therapeutic medications. "
01/01/2014 - "This review highlights liver physiological functions, altered DMEs, and altered drug disposition in liver diseases. "
01/01/2014 - "The activity and expression of several key DMEs are changed in various liver diseases and thus lead to significantly altered drug disposition. "
|4.||Breast Neoplasms (Breast Cancer)
07/01/2013 - "Despite its limitations, this is the first study that assesses the role of genetic polymorphisms in DMEs with breast cancer in a sample of Lebanese women. "
07/01/2013 - "To the best of our knowledge, this is the first study that evaluated the effect of a large array of nearly 2000 polymorphisms in DMEs and transporters on docetaxel toxicity in breast cancer patients, and in a previously understudied population. "
06/01/2007 - "We have analyzed several members of drug-metabolizing enzymes (DMEs) and other polymorphisms in genes implicated in tumor aggressivity regarding possible links between specific genetic variability in systemic drug bioavailability and toxicity in breast cancer patients treated with adjuvant anthracycline-based treatment. "
01/01/2015 - "Interestingly, some DMEs were suggested to act as tumor-suppressor or housekeeper based on their unique DNA methylation features. "
12/01/2014 - "Considering the dual roles of TKIs on both DMEs and drug transporters, and the importance of these enzyme and transporters in drug disposition, the potential for enzyme- and transporter-mediated TKI-drug interactions in patients with cancer is an important consideration. "
10/01/2014 - "In combination with the data retrieved in vitro tumor cell lines, we discussed the similarities and differences of DMEs expression and function between tumor tissues (in vivo) and tumor cells (in vitro), and proposed the possible factors that cause the differences."
12/01/2007 - "The contribution of tumoural DMEs to cancer therapy can only be ascertained through large prospective studies and supported by new technologies. "
07/02/2001 - "Genetic differences in the regulation, expression and activity of genes coding for Phase I and Phase II DMEs and DME receptors that control DME activity levels, can be crucial factors in defining cancer susceptibility and the toxic or carcinogenic power of environmental chemicals. "
|1.||protein kinase C beta
|3.||Cytoplasmic and Nuclear Receptors (Nuclear Receptors)
|4.||Transcription Factors (Transcription Factor)
|9.||pregnane X receptor
|10.||Toll-Like Receptors (Toll-Like Receptor)
|1.||Drug Therapy (Chemotherapy)